Pten依赖性区分了血液形成干细胞和白血病发起细胞
Omer H Yilmaz1, Riccardo Valdez, Brian K Theisen
1Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA.
Nature
|April 7, 2006
概括
针对癌症干细胞和正常造血干细胞 (HSC) 之间的机制差异可以导致有效的疗法. 在HSC中Pten缺失导致白血病,但也导致HSC枯竭,与癌细胞不同,这种差异被拉巴素抑制.
科学领域:
- 血液学 血液学 血液学
- 癌症生物学 癌症生物学
- 干细胞生物学 干细胞生物学
背景情况:
- 正常干细胞和癌症干细胞具有功能上的相似性.
- 在不损害正常干细胞的情况下,开发选择性消除癌症干细胞的疗法是一个关键的挑战.
研究的目的:
- 调查是否针对正常干细胞和癌症干细胞之间的机制差异可以导致选择性癌症治疗.
- 确定Pten和mTOR通路在区分正常造血干细胞 (HSC) 行为与白血病发起细胞中的作用.
主要方法:
- 在老鼠的成年造血细胞中条件删除Pten瘤抑制基因.
- 诱导骨髓增殖性疾病和移植性白血病.
- 血液造血干细胞 (HSC) 增殖和复合能力的评估.
- 评估拉巴胺,一种mTOR抑制剂对正常的HSC和白血病发起细胞的影响.
主要成果:
- 在造血细胞中的Pten缺失迅速诱导骨髓增殖性疾病和白血病.
- 的删除促进了HSC的扩散,但矛盾的是,导致了HSC的枯竭,阻止了稳定的复制.
- 不同于HSCs,白血病发起细胞可以在没有Pten.的情况下维持自身.
- 拉巴胺治疗抑制了Pten删除诱导的效应,耗尽了白血病发起细胞,并恢复了正常的HSC功能.
结论:
- 正常的HSC和白血病发起细胞之间存在机制上的差异,特别是关于Pten依赖性.
- mTOR途径是这些差异的关键调解者,并代表了一个可行的治疗点.
- 针对这些特定的分子通路提供了一种选择性消除癌症干细胞的策略,同时保持正常的HSC功能.
相关概念视频
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:21Hematopoiesis
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
01:21Lineage Commitment
Commitment is the process whereby stem cells:
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:27Source And Potency Of Stem Cells
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...